Compare ETD & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETD | HELP |
|---|---|---|
| Founded | 1932 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.7M | 504.6M |
| IPO Year | 1996 | N/A |
| Metric | ETD | HELP |
|---|---|---|
| Price | $23.35 | $7.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $27.00 | ★ $51.50 |
| AVG Volume (30 Days) | 414.2K | ★ 1.6M |
| Earning Date | 04-29-2026 | 07-01-2026 |
| Dividend Yield | ★ 8.15% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.10 | N/A |
| Revenue | ★ $766,784,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.73 | N/A |
| P/E Ratio | $20.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.28 | $3.76 |
| 52 Week High | $31.41 | $8.55 |
| Indicator | ETD | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 55.37 | 66.00 |
| Support Level | $22.41 | $4.18 |
| Resistance Level | $25.12 | $8.50 |
| Average True Range (ATR) | 0.67 | 0.52 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 51.48 | 78.54 |
Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.